Overview

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Status:
Recruiting

Trial end date:
2025-08-01

Target enrollment:

Participant gender:

Summary

This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.

Phase:

Phase 2

Details

Lead Sponsor:

Melanoma Institute Australia

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab